Roche's new crown oral drug failed phase II clinical progress and how is the clinical progress of the other 4 companies

Recently, Roche and Atea Pharmaceuticals announced that their new crown oral drug AT-527 global phase II trial MOONSONG did not meet the primary endpoint

AT-527 was developed by Atea.

The phase II clinical trial of AT-5272 is mainly used to treat patients with moderate COVID-19 who need to be hospitalized and patients with mild to moderate COVID-19 who are not hospitalized.

However, for high-risk patients with underlying health problems (underlying diseases), on the seventh day in the 550 mg and 1100 mg dose groups, the viral load was reduced by 0.

Roche and Atea believe that the wide selection of patients in clinical enrollment may be the cause of clinical failure, and the difference is not significant compared with the control group

At present, in terms of the development of new crown oral drugs, Pfizer, Merck, Shiono Yoshihide, and Kaike Pharmaceutical are also in the layout and are in the late stage of research and development.

Molnupiravir is a small-molecule broad-spectrum antiviral oral drug for RNA viruses that can inhibit the replication of the new coronavirus.

In fact, based on confidence in the research results, Merck is already taking risks to produce Molnupiravir ahead of schedule, and is expected to be able to produce enough drugs for 10 million treatment courses in 2021, and will continue to increase drug supply in 2022

For Pfizer, the 3CL protease inhibitor PF-07321332 + ritonavir therapy will usher in Phase III data unblinding before the end of the year.

For Shiono Yoshihide, Japan, S-217622, ​​which is also a 3CL protease inhibitor, is currently undergoing phase 2/3 clinical trials in patients with mild or asymptomatic new crown infections

In terms of pioneering the pharmaceutical industry, the androgen receptor antagonist procrulamide will unblind the phase III data in mid-November